Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

Urology

Volumn 63, Issue 4, 2004, Pages 709-715

  Roehrborn, Claus G ^a   Marks, Leonard S ^b   Fenter, Tom ^b   Freedman, Sheldon ^b   Tuttle, John ^b   Gittleman, Marc ^b   Morrill, Betsy ^b   Wolford, Eric T ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINE FLOW RATE; URINE RETENTION;

AGED; AZASTEROIDS; DOUBLE-BLIND METHOD; EJACULATION; ENZYME INHIBITORS; GYNECOMASTIA; HUMANS; IMPOTENCE; ISOENZYMES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLACEBOS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME; URODYNAMICS;

EID: 1842688886     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.01.001     Document Type: Article

References (10)

1. Napalkov P, Maisonneuve P, and Boyle P: Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 46(3 suppl A): 41-46, 1995
2. Oesterling J.E. Benign prostatic hyperplasia a review of its histogenesis and natural history. Prostate Suppl. 6:1996;67-73.
3. Wasson J.H., Reda D.J., Bruskewitz R.C., et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med. 332:1995;75-79.
4. Roehrborn C.G., Boyle P., Nickel C., et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 60:2002;434-441.
5. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
6. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia a double-blind, placebo-controlled, multicenter study. Urology. 51:1998;677-686.
7. Rhodes T., Girman C.J., Jacobsen S.J., et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 161:1999;1174-1179.
8. Roehrborn C.G., McConnell J., Bonilla J., et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol. 163:2000;13-20.
9. Sech S.M., Montoya J.D., Bernier P.A., et al. The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology. 51:1998;242-250.
10. Barry M.J., Williford W.O., Chang Y., et al. Benign prostatic hyperplasia specific health status measures in clinical research how much change in the American Urological Association Symptom Index is perceptible to patients? J Urol. 154:1995;1770-1774.